224 related articles for article (PubMed ID: 30160791)
21. An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.
Bromley D; Bauer MR; Fersht AR; Daggett V
Protein Eng Des Sel; 2016 Sep; 29(9):377-90. PubMed ID: 27503952
[TBL] [Abstract][Full Text] [Related]
22. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
[TBL] [Abstract][Full Text] [Related]
23. Factors governing loss and rescue of DNA binding upon single and double mutations in the p53 core domain.
Wright JD; Noskov SY; Lim C
Nucleic Acids Res; 2002 Apr; 30(7):1563-74. PubMed ID: 11917017
[TBL] [Abstract][Full Text] [Related]
24. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening.
Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M
J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488
[TBL] [Abstract][Full Text] [Related]
25. ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation.
Morton DJ; Patel D; Joshi J; Hunt A; Knowell AE; Chaudhary J
Oncotarget; 2017 Jan; 8(2):2536-2549. PubMed ID: 27911860
[TBL] [Abstract][Full Text] [Related]
26. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations.
Joerger AC; Allen MD; Fersht AR
J Biol Chem; 2004 Jan; 279(2):1291-6. PubMed ID: 14534297
[TBL] [Abstract][Full Text] [Related]
27. Hot-spot mutants of p53 core domain evince characteristic local structural changes.
Wong KB; DeDecker BS; Freund SM; Proctor MR; Bycroft M; Fersht AR
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8438-42. PubMed ID: 10411893
[TBL] [Abstract][Full Text] [Related]
28. Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions.
Eldar A; Rozenberg H; Diskin-Posner Y; Rohs R; Shakked Z
Nucleic Acids Res; 2013 Oct; 41(18):8748-59. PubMed ID: 23863845
[TBL] [Abstract][Full Text] [Related]
29. Wrapping effects within a proposed function-rescue strategy for the Y220C oncogenic mutation of protein p53.
Accordino SR; Rodríguez Fris JA; Appignanesi GA
PLoS One; 2013; 8(1):e55123. PubMed ID: 23365691
[TBL] [Abstract][Full Text] [Related]
30. Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket.
Pradhan MR; Siau JW; Kannan S; Nguyen MN; Ouaray Z; Kwoh CK; Lane DP; Ghadessy F; Verma CS
Nucleic Acids Res; 2019 Feb; 47(4):1637-1652. PubMed ID: 30649466
[TBL] [Abstract][Full Text] [Related]
31. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G; Wiman KG
Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation Regulates the Bound Structure of an Intrinsically Disordered Protein: The p53-TAZ2 Case.
Ithuralde RE; Turjanski AG
PLoS One; 2016; 11(1):e0144284. PubMed ID: 26742101
[TBL] [Abstract][Full Text] [Related]
33. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.
Basse N; Kaar JL; Settanni G; Joerger AC; Rutherford TJ; Fersht AR
Chem Biol; 2010 Jan; 17(1):46-56. PubMed ID: 20142040
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.
Punganuru SR; Madala HR; Venugopal SN; Samala R; Mikelis C; Srivenugopal KS
Eur J Med Chem; 2016 Jan; 107():233-44. PubMed ID: 26599530
[TBL] [Abstract][Full Text] [Related]
35. Structural and sequential context of p53: A review of experimental and theoretical evidence.
Saha T; Kar RK; Sa G
Prog Biophys Mol Biol; 2015 Mar; 117(2-3):250-263. PubMed ID: 25550083
[TBL] [Abstract][Full Text] [Related]
36. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate.
Knights CD; Catania J; Di Giovanni S; Muratoglu S; Perez R; Swartzbeck A; Quong AA; Zhang X; Beerman T; Pestell RG; Avantaggiati ML
J Cell Biol; 2006 May; 173(4):533-44. PubMed ID: 16717128
[TBL] [Abstract][Full Text] [Related]
37. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
38. Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer.
Miller JJ; Orvain C; Jozi S; Clarke RM; Smith JR; Blanchet A; Gaiddon C; Warren JJ; Storr T
Chemistry; 2018 Dec; 24(67):17734-17742. PubMed ID: 30230059
[TBL] [Abstract][Full Text] [Related]
39. Structure-based rescue of common tumor-derived p53 mutants.
Wieczorek AM; Waterman JL; Waterman MJ; Halazonetis TD
Nat Med; 1996 Oct; 2(10):1143-6. PubMed ID: 8837616
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
